Valbiotis presents the results of its phase I/II clinical trial to evaluate TOTUM•63 (active ingredient of Valedia®) for managing prediabetes at the 77th scientific sessions of American Diabetes Association – San Diego Convention Center, San Diego (California, USA), from June 9 to 13, 2017.
